Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide in MASLD and Obesity
NCT06934642Phase 1Recruiting
- Sponsor
- The University of New Mexico
- Start
- Jun 2025
- Primary completion
- Oct 2026
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tirzepatide in metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity, sponsored by The University of New Mexico. Primary endpoint: Biomarkers associated with MASLD at 12 months. Started Jun 2025; status: recruiting.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)obesity
Beyond the preview
Go deeper on NCT06934642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934642.